Outcomes with novel combinations in non-clear cell renal cell carcinoma (nccRCC): ORACLE study

被引：0

作者：

Kilari, D. ^{[1
]}

Szabo, A. ^{[2
,3
]}

Bilen, M. A. ^{[4
]}

Ged, Y. ^{[5
]}

Maughan, B. L. ^{[6
]}

Hwang, C. ^{[7
]}

McManus, H. ^{[8
]}

Barata, P. M. Coelho ^{[9
]}

Desai, A. ^{[10
]}

Zakharia, Y. ^{[11
]}

Emamekhoo, H. ^{[12
]}

Tripathi, A. ^{[13
]}

Rose, T. ^{[14
]}

Ghatalia, P. ^{[15
]}

Reimers, M. A. ^{[16
]}

Heath, E. ^{[17
]}

King, J. M. ^{[18
]}

Rini, B. I. ^{[19
]}

Brugarolas, J. ^{[20
]}

Mckay, R. R. ^{[21
]}

机构：

[1] Med Coll Wisconsin, Dept Med, Milwaukee, WI 53226 USA

[2] Froedtert Hosp, Med, Milwaukee, WI USA

[3] Med Coll Wisconsin, Milwaukee, WI 53226 USA

[4] Emory Univ, Dept Oncol, Winship Canc Inst, Atlanta, GA 30322 USA

[5] Johns Hopkins Univ Hosp, Dept Oncol, Baltimore, MD USA

[6] Univ Utah Hlth, Div Med Oncol, Dept Internal Med, Huntsman Canc Inst, Salt Lake City, UT USA

[7] Henry Ford Hlth, Internal Med Hematol Oncol, Henry Ford Canc Inst, Detroit, MI USA

[8] Duke Univ, Med Ctr, Med, Durham, NC USA

[9] Univ Hosp Seidman Canc Ctr, Dept Internal Med, Cleveland, OH USA

[10] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA

[11] Univ Iowa Hosp & Clin, Dept Internal Med, Iowa City, IA 52242 USA

[12] UW Carbone Canc Ctr, Hematol Oncol, Madison, WI USA

[13] City Hope Comprehens Canc Ctr, Dept Med Oncol & Therapeut Res, Duarte, CA USA

[14] UNC Lineberger Comprehens Canc Ctr, Med, Chapel Hill, NC USA

[15] Fox Chase Canc Ctr Main Campus, 1Med Oncol, Philadelphia, PA USA

[16] Washington Univ, Sch Med, Dept Internal Med, St Louis, MO 63110 USA

[17] Karmanos Canc Inst, Oncol, Detroit, MI USA

[18] Indiana Univ, Simon Canc Ctr, Med Oncol, Indianapolis, IN 46204 USA

[19] Vanderbilt Ingram Canc Ctr, Dept Oncol, Nashville, TN USA

[20] UT Southwestern Med Ctr, Dallas, TX USA

[21] Univ Calif San Diego, Dept Med, San Diego, CA 92103 USA

来源：

ANNALS OF ONCOLOGY | 2024年 / 35卷

关键词：

D O I：

10.1016/j.annonc.2024.08.1802

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1709P

引用

页码：S1024 / S1025

页数：2

共 50 条

[21] Renal cell carcinoma: evolving approaches to advanced non-clear cell carcinoma
Heng, Daniel Y. C.
Bukowski, Ronald M.
ONCOLOGY REVIEWS, 2007, 1 (03) : 170 - 176
[22] Metastatic non-clear cell renal cell carcinoma (nccRCC) treated with targeted therapy agents: Applying the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) prognostic model to predict outcomes
Kroeger, Nils
Xie, Wanling
Lee, Jae-Lyun
Bjarnason, Georg A.
Knox, Jennifer J.
MacKenzie, Mary J.
Wood, Lori
Srinivas, Sandy
Vaishamayan, Ulka N.
Rha, Sun Young
Pal, Sumanta Kumar
Donskov, Frede
Agarwal, Neeraj
Kollmannsberger, Christian K.
Tan, Min-Han
North, Scott A.
Rini, Brian I.
Choueiri, Toni K.
Heng, Daniel Yick Chin
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
[23] Node positive non-clear cell renal cell carcinoma: Oncological outcomes and genomic insights
Eismann, L.
Zucker, M.
Dawidek, M.
Reese, S.
Calderon, Posada L.
Aulitzky, A.
Stief, C.
Coleman, J.
Kotecha, R.
Carlo, M.
Chen, Y.
Reznik, E.
Russo, P.
Hakimi, A.
EUROPEAN UROLOGY, 2024, 85 : S2159 - S2159
[24] Long-term treatment outcomes of patients with non-clear cell renal cell carcinoma
Mukhomedyarova, A. A.
Alekseev, B. Ya
Kalpinskiy, A. S.
ONKOUROLOGIYA, 2021, 17 (03): : 39 - 46
[25] The incidence, pathogenesis, and management of non-clear cell renal cell carcinoma
Naik, Priyanka
Dudipala, Harshitha
Chen, Yu-Wei
Rose, Brent
Bagrodia, Aditya
Mckay, Rana R.
THERAPEUTIC ADVANCES IN UROLOGY, 2024, 16
[26] Clinical activity of ipilimumab plus nivolumab (Ipi/Nivo) in patients (pts) with metastatic non-clear cell renal cell carcinoma (nccRCC).
Gupta, Ruby
Ornstein, Moshe Chaim
Gul, Anita
Allman, Kimberly D.
Ball, Jessica
Wood, Laura S.
Garcia, Jorge A.
VonMerveldt, Dendra
Hammers, Hans J.
Rini, Brian I.
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[27] Outcomes of patients (pts) with metastatic non-clear-cell renal cell carcinoma (nccRCC) treated with pazopanib
Matrana, Marc Ryan
Baiomy, Ali
Elsayes, Khaled M.
Shetty, Aditya
Teegavarapu, Purnima Sravanti
Xiao, Lianchun
Jonasch, Eric
Tannir, Nizar M.
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
[28] Nivolumab (nivo) for patients (pts) with metastatic non-clear cell renal cell carcinoma (nccRCC): A single-institution experience.
Chahoud, Jad
Campbell, Matthew T.
Gao, Jianjun
Zurita, Amado J.
Shah, Amishi Yogesh
Msaouel, Pavlos
Ross, Jeremy Aaron
Xiao, Lianchun
Jonasch, Eric
Sharma, Padmanee
Tannir, Nizar M.
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[29] Clinical activity of PD1/PDL1 inhibitors in metastatic non-clear cell renal cell carcinoma (nccRCC).
Moreira, Raphael Brandao
McKay, Rana R.
Xie, Wanling
Heng, Daniel Yick Chin
de Velasco, Guillermo
Castellano, Daniel E.
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
[30] Atezolizumab plus bevacizumab in non-clear cell renal cell carcinoma (NccRCC) and clear cell renal cell carcinoma with sarcomatoid differentiation (ccRCCsd): Updated results of activity and predictive biomarkers from a phase II study.
Flippot, Ronan
McGregor, Bradley Alexander
Flaifel, Abdallah
Gray, Kathryn P.
Signoretti, Sabina
Steinharter, John A.
Van Allen, Eliezer Mendel
Walsh, Meghara K.
Gundy, Katy
Wei, Xiao X.
Harshman, Lauren Christine
Vaishampayan, Ulka N.
Choueiri, Toni K.
McKay, Rana R.
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)

← 1 2 3 4 5 →